Cite
HARVARD Citation
Ono, T. et al. (2023). Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML. Cancer science. 114 (3), pp. 995-1006. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Ono, T. et al. (2023). Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML. Cancer science. 114 (3), pp. 995-1006. [Online].